Cemiplimab shows strong survival benefit in KRAS G12C positive advanced NSCLC

Prof David Gandara speaks to ecancer about the genomic analysis from the phase III EMPOWER-Lung 1 study.

This study examines the impact of co-occurring genomic alterations on the efficacy of first-line cemiplimab in patients with advanced non-squamous NSCLC and PD-L1 expression of 50% or higher.

Prof Gandara highlights that patients with KRAS mutations, particularly KRAS G12C, derived substantial overall and progression-free survival benefits with cemiplimab compared with chemotherapy, with objective response rates also favouring immunotherapy.

He explores the potential predictive role of KRAS G12C, as well as the impact of TP53, STK11, KEAP1 and tumour mutational burden on treatment outcomes.